Vivopower Plc (VIVO) Stock Price, Quote & News

ProFloats Mar. 16 at 7:35 PM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $VIVO $BYND $BITF Sprouting

0 · Reply

VivoPower_Official Mar. 16 at 3:24 PM

Major update: VivoPower’s new Nasdaq ticker $VIVO is now effective, along with the company’s corporate name change to VivoPower PLC. The move reflects the company’s evolving strategy focused on powered land and AI data center infrastructure as global demand for compute and energy-secured sites continues to grow. Key points: • Ticker change: $VVPR → $VIVO • Corporate name officially updated • No action required for existing shareholders • Strategic focus on AI infrastructure & powered land To stay informed or learn more, visit the new website: http://vivopower.com Do your own research. #AI #Datacenters #Nasdaq

0 · Reply

Rockwell101 Mar. 16 at 3:22 PM

$VIVO So VVPR is trading at $33.98? I am rich!

0 · Reply

thegoodnessparadox Mar. 16 at 1:59 PM

$VIVO Boo!

0 · Reply

thegoodnessparadox Mar. 16 at 1:58 PM

$VIVO Yeah!

0 · Reply

SebKalla Mar. 16 at 11:21 AM

$VVPR how is $VIVO TRADING BOYS AND GIRLS? Hahaha

0 · Reply

VivoPower_Official Mar. 10 at 2:48 PM

$VVPR ➜ $VIVO VivoPower announced it will change its Nasdaq ticker to $VIVO effective March 16, 2026, alongside a corporate name change to VivoPower PLC. The change reflects the company’s focus on AI data center infrastructure and powered land development. No action required from shareholders.

0 · Reply

TheTradeXchange Feb. 24 at 1:00 PM

$VIVO Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio

0 · Reply

DogePeoplesCoin Feb. 18 at 5:42 PM

$VVOS Great chat!! It is a go time for $VIVO!

0 · Reply

StocktwitsGPT Aug. 1 at 7:59 PM

$VIVO - Meridian Bioscience Inc Bull Case: COVID-19 Tailwind: Meridian Bioscience has benefited from increased demand for diagnostic tests during the pandemic, driving revenue growth. Diversified Portfolio: The company's broad range of diagnostic products for gastrointestinal and respiratory illnesses provides stability and growth potential. Strong Financials: Solid revenue performance and profitability metrics suggest a healthy financial position, making it an attractive investment. Bear Case: Post-Pandemic Decline: As COVID-19 testing demand declines, the company may face revenue challenges in the near term. Regulatory Risks: Stringent regulatory requirements for medical diagnostics can pose challenges and delays in product approvals. Market Saturation: High competition in the diagnostics market could limit Meridian's market share and pricing power. Source: MarketWatch, Seeking Alpha

0 · Reply

VivoPower Announces Effectiveness of New Stock Ticker “VIVO” and Corporate Name Change

Feb 24, 2026, 8:00 AM EST - 21 days ago

Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio

Jan 31, 2023, 1:56 PM EST - 3 years ago

SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience

Dec 12, 2022, 8:00 AM EST - 3 years ago

Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger

Nov 22, 2022, 8:00 AM EST - 3 years ago

MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS

Sep 26, 2022, 12:00 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TMX, VIVO, RFP, SBTX

RFP

Aug 22, 2022, 9:34 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates RFP, VIVO, EGY, STCN

EGY RFP STCN

Aug 15, 2022, 9:00 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates BHVN, VIVO, HNGR, CMAX

BHVN

Aug 8, 2022, 12:00 AM EDT - 3 years ago

SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, ONEM, HNGR

Aug 5, 2022, 8:00 AM EDT - 3 years ago

MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS

Jul 29, 2022, 9:23 AM EDT - 3 years ago

Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay

Jul 27, 2022, 10:10 PM EDT - 3 years ago

MERIDIAN BIOSCIENCE INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

Jul 7, 2022, 6:59 PM EDT - 4 years ago

MERIDIAN BIOSCIENCE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Meridian Bioscience, Inc. - VIVO

Jul 7, 2022, 7:32 AM EDT - 4 years ago

Meridian Bioscience agrees to $1.5 billion buyout by SD Biosensor, SJL Partners

Jul 7, 2022, 7:17 AM EDT - 4 years ago

Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction

Jul 7, 2022, 7:12 AM EDT - 4 years ago

Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter

Jul 5, 2022, 10:15 PM EDT - 4 years ago

Meridian Bioscience Is Not Your Average Life Science Company

Jun 20, 2022, 8:38 AM EDT - 4 years ago

Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays

May 26, 2022, 1:31 PM EDT - 4 years ago

Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests

May 23, 2022, 1:13 PM EDT - 4 years ago

Meridian Bioscience to Participate in the 2022 H.C. Wainwright Global Investment Conference

May 17, 2022, 3:33 PM EDT - 4 years ago

Meridian Bioscience Launches Lyo-Ready™ Saliva-Specific Isothermal Amplification Master Mixes for Direct Detection of DNA & RNA in Point of Care Diagnostic Assays

May 6, 2022, 3:15 PM EDT - 4 years ago

Meridian Bioscience's Q2 Revenues Increase 30% To $111M, Highest In Company History

May 6, 2022, 1:25 PM EDT - 4 years ago

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q2 2022 Results - Earnings Call Transcript

May 6, 2022, 8:00 AM EDT - 4 years ago

MERIDIAN BIOSCIENCE REPORTS RECORD SECOND QUARTER FISCAL 2022 OPERATING RESULTS

May 2, 2022, 8:47 AM EDT - 4 years ago

Meridian Acquires EUPROTEIN to Further Expand Recombinant Protein Capabilities

Apr 7, 2022, 8:35 AM EDT - 4 years ago

Meridian Bioscience Announces Preliminary Net Revenues Results for Fiscal 2022 Second Quarter

Mar 29, 2022, 2:37 PM EDT - 4 years ago

Meridian Bioscience Launches Lyo-Ready™ qPCR Inhibitor Tolerant Blood-Specific Master Mixes for DNA & RNA Direct Detection

Feb 21, 2022, 9:00 AM EST - 4 years ago

Meridian Bioscience Names Andy Kitzmiller as Chief Financial Officer

Feb 16, 2022, 9:05 AM EST - 4 years ago

Magellan Diagnostics Resumes Distribution of LeadCare® II Test Kits

Feb 13, 2022, 8:52 AM EST - 4 years ago

S&P 500 Stocks With Strong Momentum

AA AMPH BCC CF COOP COP CVX

Feb 12, 2022, 8:49 AM EST - 4 years ago

Impactive Capital brings a sustainable brand of activism to Meridian Bioscience

Feb 4, 2022, 2:03 PM EST - 4 years ago

Meridian Bioscience, Inc.'s (VIVO) CEO Jack Kenny on Q1 2022 Results - Earnings Call Transcript

Feb 4, 2022, 11:30 AM EST - 4 years ago

Why Meridian Bioscience's Shares Are Rising Today?

Feb 4, 2022, 8:00 AM EST - 4 years ago

MERIDIAN BIOSCIENCE REPORTS SECOND BEST QUARTER IN COMPANY HISTORY

Jan 31, 2022, 11:45 AM EST - 4 years ago

Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel

Jan 28, 2022, 10:05 AM EST - 4 years ago

Meridian Bioscience Launches Lyo-Ready™ qPCR Saliva-Specific Master Mixes for DNA & RNA Direct Detection

Jan 27, 2022, 2:05 PM EST - 4 years ago

Meridian Bioscience Elects John C. McIlwraith New Chairman of the Board

Jan 10, 2022, 10:05 AM EST - 4 years ago

Meridian Bioscience to Hold First Quarter 2022 Financial Results Conference Call on February 4, 2022

Jan 5, 2022, 10:15 AM EST - 4 years ago

Meridian Bioscience Receives FDA-Clearance for the Curian® Campy Assay

Jan 4, 2022, 2:00 PM EST - 4 years ago

Meridian Bioscience to Participate in the 2022 H. C. Wainwright Bioconnect Virtual Conference

Dec 14, 2021, 12:23 PM EST - 4 years ago

3 Stocks With Low PEG Ratios

AMPH JOUT

Dec 2, 2021, 8:00 AM EST - 4 years ago

Meridian Bioscience Announces Retirement of CFO Bryan Baldasare

Nov 24, 2021, 9:05 AM EST - 4 years ago

Meridian Bioscience Announces Retirement of Chairman David Phillips

Nov 17, 2021, 10:05 AM EST - 4 years ago

Meridian Launches Two New Air-Dryable™ Mixes for Isothermal Amplification, Powering Shortest Time-to-results in Point-of-care Testing

Nov 12, 2021, 1:26 PM EST - 4 years ago

Meridian Bioscience, Inc. (VIVO) CEO Jack Kenny on Q4 2021 Earnings Conference Call - Earnings Call Transcript

Nov 12, 2021, 11:45 AM EST - 4 years ago

Meridian Bioscience's Q4 Earnings Beat Expectations

ProFloats Mar. 16 at 7:35 PM

Caught a few of @TheMorningStew plays over the last few weeks that went crazy! Give him a follow 🔥 $VIVO $BYND $BITF Sprouting

0 · Reply

VivoPower_Official Mar. 16 at 3:24 PM

0 · Reply

Rockwell101 Mar. 16 at 3:22 PM

$VIVO So VVPR is trading at $33.98? I am rich!

0 · Reply

thegoodnessparadox Mar. 16 at 1:59 PM

$VIVO Boo!

0 · Reply

thegoodnessparadox Mar. 16 at 1:58 PM

$VIVO Yeah!

0 · Reply

SebKalla Mar. 16 at 11:21 AM

$VVPR how is $VIVO TRADING BOYS AND GIRLS? Hahaha

0 · Reply

VivoPower_Official Mar. 10 at 2:48 PM

0 · Reply

TheTradeXchange Feb. 24 at 1:00 PM

$VIVO Meridian Bioscience Achieves IVDR Certification for Alethia® Molecular Assay Portfolio

0 · Reply

DogePeoplesCoin Feb. 18 at 5:42 PM

$VVOS Great chat!! It is a go time for $VIVO!

0 · Reply

StocktwitsGPT Aug. 1 at 7:59 PM

0 · Reply

bergini Nov. 30 at 4:03 PM

$MINM looking alot like $VIVO yesterday, held up great troughout the day the go absolutely banans closing in on PH, could we see 18-20$?

0 · Reply

bergini Nov. 29 at 10:34 PM

$MOTS sooner or later this shit will go parabolic just a matter of time, FDA clearance, under a million in float, throughout Q1 2024. Every parameter to run hard in the current state the market is in. $CYTOF $VIVO

2 · Reply

Market Cap	1.49B
Revenue (ttm)	333.02M
Net Income (ttm)	42.46M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	704,434
Avg Vol	886,610
Day's Range	N/A - N/A
Shares Out	43.83M
Stochastic %K	36%
Beta	0.26
Analysts	Hold
Price Target	$34.00